抗菌薬・抗微生物薬の選び方・使い方Q&A

出版社： 文光堂
著者：
発行日： 2014-08-18
分野： 臨床医学：内科  >  感染症/AIDS
ISBN： 9784830681547
電子書籍版： 2014-08-18 （第1版第2刷）
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安：8～14営業日

6,050 円(税込)

購入する
電子書籍
章別単位での購入はできません
ブラウザ、アプリ閲覧

6,050 円(税込)

購入する

商品紹介

数ある抗菌薬・抗微生物薬を上手に使い分けるにはどうするか．医師が現場でぶつかる処方の初歩的な悩みに始まり，各系統の薬剤ごとの特徴と使い分けのコツを解説する．

目次

  • 抗菌薬・抗微生物薬の選び方・使い方Q&A

    ―目次―

    I．総論まず基本を知るべし！
    １. まず押さえておくべき基本中の基本
    　1）適切な抗微生物薬治療とは
    　2）抗微生物薬治療にはどのような検査が役に立ちますか？
    　3）抗微生物薬の選択のため知っておきたい病原体の知識って？
    ２. 臨床薬理で知っておきたいこと
    　1）抗微生物薬のPK/PD理論って何ですか？
    　2）抗微生物薬のTDMって何ですか？
    　3）どんな副作用に注意したらよいですか？
    　4）薬物相互作用としてどんなことに注意が必要ですか？
    ３. ライフサイクルと抗菌薬・抗微生物薬
    　1）高齢者へ抗微生物薬投与するときは，
    　　　どのような点に注意しますか？
    　トピックス 簡易懸濁法ってどうすればいいの？
    　2）子どもへの投与はどうするの？
    　　　〜悩ましいセレクト・タイミング・投与量の考え方〜
    　トピックス 妊婦での使用で注意すべきことは？
    ４. ワンランク上の抗微生物薬治療
    　　　〜賢く併用，感染制御，そして限界〜
    　1）抗菌薬・抗微生物薬を併用するのはどんなときですか？
    　2）感染制御のための抗菌薬の適正使用法は？
    　3）抗菌薬では太刀打ちできないときは？
    　トピックス 耐性はどうしてできる？
    ５. 特殊な病態での使い方
    　1）好中球減少時にはどんな抗微生物薬治療がいいのですか？
    　2）集中治療における抗微生物薬治療の留意点
    　3）周術期抗菌薬に何をどう選ぶ？
    　4）腎・肝障害があるときはどうしたらよいですか？
    　トピックス バイオフィルム関連感染症って何ですか？
    ６. 抗菌薬・抗微生物薬の局所療法
    　1）眼科領域の抗微生物薬局所療法について教えて！
    　2）呼吸器領域の抗微生物薬局所療法について教えて！
    　3）皮膚科領域の抗微生物薬局所療法について教えて！
    　4）抗菌薬含有骨セメントって何？灌流って？
    　　　〜整形外科特有の局所療法〜
    　トピックス プロバイオティクスって使えるの？

    II．各論：色々な抗菌薬・抗微生物薬のＱ＆Ａ
    　　　〜効くメカニズム・適応・留意点・薬剤耐性〜
    １. 抗菌薬
    　1）ペニシリン系抗菌薬（β-ラクタマーゼ阻害薬配合剤を含む）
    　　　を使いこなすには？
    　トピックス β-ラクタム系抗菌薬アレルギーについて
    　　　知っておくべきことって？
    　2）セファロスポリン系抗菌薬〜いろいろあるけどどう使う？〜
    　3）モノバクタム系抗菌薬の使い時は？
    　4）カルバペネム系抗菌薬を賢く使うには？
    　5）アミノグリコシド系抗菌薬の使い方は？
    　6）キノロン系抗菌薬の上手な使い方は？
    　トピックス コリスチンについて知っておくべきことって？
    　7）マクロライド・リンコマイシン系抗菌薬のうまい使い方は？
    　トピックス 性感染症治療のポイントは？
    　トピックス 抗菌薬の抗炎症作用って何ですか？
    　8）テトラサイクリン系抗菌薬ってどんなときに使うの？
    　　　　〜DOXYとMINOの特徴と適応〜
    　トピックス グリシルサイクリン系抗菌薬（チゲサイクリン）の
    　　　　　　　　出番はどんなとき？
    　トピックス ホスホマイシンはどう使うの？
    　9）グリコペプチド系抗菌薬の使い分けは？
    　トピックス ストレプトグラミン系抗菌薬
    　　　　　　(キヌプリスチン・ダルホプリスチン)って何ですか？
    　10）リネゾリド・ダプトマイシンを賢く使うには？
    　11）ST合剤の使い方は？〜故きを温ねて新しきを知る〜
    　12）メトロニダゾールを賢く使うには？
    　13）抗結核薬（リファマイシン系・イソニアジド・
    　　　　エタンブトール・ピラジナミドなど）の使い方は？
    ２. 抗真菌薬
    　1）アゾール系抗真菌薬の使い分けはどうするの？
    　2）キャンディン系抗真菌薬の使い方は？
    　3）ポリエン系抗真菌薬の出番はどんな時？
    　トピックス フルシトシンはいつ使うの？
    ３. 抗ウイルス薬
    　1）抗ヘルペスウイルス薬の使い方は？
    　2）抗サイトメガロウイルス薬を賢く使うには？
    　3）抗インフルエンザウイルス薬はどう使い分けるの？
    　4）抗肝炎ウイルス薬にはどんなものがありますか？
    　5）抗HIV 薬の種類と使い方は？
    ４. 抗原虫薬
    　1）抗原虫薬の種類と使い方は？
    　トピックス 今後，日本で使えるようになるかもしれない
    　　　　　　　　抗微生物薬教えます

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

I. 総論 まず基本を知るべし !

P.20 掲載の参考文献
1) Higuchi K, et al. : Comparison of performance in two diagnostic methods for tuberculosis infection. Med Microbiol Immunol 198 : 33-37, 2009.
PubMed
2) Wacker C, et al. : Procalcitonin as a diagnostic marker for sepsis ; a systematic review and meta-analysis. Lancet Infect Dis 13 (5) : 426-435, 2013.
PubMed
3) Clark AE, et al. : Matrix-assisted laser desorption ionization-time of flight mass spectrometry ; a fundamental shift in the routine practice of clinical microbiology. Clin Microbiol Rev 26 (3) : 547-603, 2013.
PubMed
4) Liu C, et al. : Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillinresistant Staphylococcus aureus infections in adults and children. Clin Infect Dis 52 (3) : e18-55, 2011.
 
5) Lee A, et al. : Detection of bloodstream infections in adults ; how many blood cultures are needed? J Clin Microbiol 45 (11) : 3546-3548, 2007.
PubMed
P.26 掲載の参考文献
1) Sandiumenge A, et al. : Impact of diversity of antibiotic use on the development of antimicrobial resistance. J Antimicrob Chemother 57 (6) : 1197-1204, 2006.
PubMed
2) World Health Organization : Guide to Good Prescribing ; A Practical Manual. World Health Organization, 1996.
 
3) Gilbert DN, et al. : The Sanford Guide To Antimicrobial Therapy 2013, 43rd ed. pp. 4-66, Antimicrobial Therapy, Inc., 2013.
 
4) Gilbert DN, et al. : The Sanford Guide To Antimicrobial Therapy 2013, 43rd ed. pp. 67-69, Antimicrobial Therapy, Inc., 2013.
 
P.32 掲載の参考文献
1) 管野利恵ほか : Tebipenem pivoxilのStreptococcus pneumoniaeおよびHaemophilus influenzaeに対する抗菌活性とマウス大腿感染モデルを用いたPK-PD解析. 日化療会誌 57 (Suppl 1) : S38-47, 2009.
 
2) 日本化学療法学会抗菌薬TDMガイドライン作成委員会, 日本TDM学会TDMガイドライン策定委員会-抗菌薬領域編 : 抗菌薬TDM ガイドライン. 日本化学療法学会, 日本TDM学会, 2012.
 
3) Nicolau DP : Optimizing outcomes with antimicrobial therapy through pharmacodynamic profiling. J Infect Chemother 9 : 292-296, 2003.
PubMed
4) Rayner CR, et al. : Clinical pharmacodynamics of linezolid in seriously ill patients treated in a compassionate use programme. Clin Pharmacokinet 42 : 1411-1423, 2003.
 
5) Eisenstein BI, et al. : Daptomycin ; from the mountain to the clinic, with essential help from Francis Tally, MD. Clin Infect Dis 50 (Suppl 1) : S10-15, 2010.
 
6) Tessier PR, et al. : Pharmacodynamic assessment of clarithromycin in a murine model of pneumococcal pneumonia. Antimicrob Agents Chemother 46 : 1425-1434, 2002.
 
7) Andes D : Pharmacokinetics and pharmacodynamics of antifungals. Infect Dis Clin North Am 20 : 679-697, 2006.
PubMed
P.38 掲載の参考文献
1) Noone P, et al. : Experience in monitoring gentamicin therapy during treatment of serious gram-negative sepsis. Br Med J 1 : 477-481, 1974.
 
2) 日本化学療法学会抗菌薬TDMガイドライン作成委員会, 日本TDM学会TDMガイドライン策定委員会-抗菌薬領域編 : 抗菌薬TDMガイドライン. 日化療会誌 60 : 393-445, 2012.
 
3) Rowland M, et al. : Clearance concepts in pharmacokinetics. J Pharmacokinet Biopharm 1 : 123-136, 1973.
 
4) 浜田幸宏ほか : ER・ICUで必要な注射用抗菌薬-エキスパートの考え方と使い方. 抗菌薬療法のコツと注意点効果的な投与法と考え方肝障害患者における抗菌薬投与. 救急・集中治療 25 : 207-213, 2013.
 
P.44 掲載の参考文献
1) 厚生労働省 : 重篤副作用疾患別対応マニュアル http://www.mhlw.go.jp/topics/2006/11/tp1122-1.html
 
2) Yates AB : Management of patients with a history of allergy to beta-lactam antibiotics. Am J Med 121 (7) : 572-576, 2008.
PubMed
3) Gruchalla RS, Primohamed M : Clinical practice. Antibiotic allergy. N Engl J Med 354 (6) : 601-609, 2006.
 
4) Wrenn K : Ceftriaxone versus cefuroxime for meningitis in children. N Engl J Med 322 (25) : 1821, 1990.
PubMed
5) 日本化学療法学会抗菌薬TDMガイドライン作成委員会, 日本TDM学会TDMガイドライン策定委員会-抗菌薬領域編 : 抗菌薬TDMガイドライン. 日本化学療法学会, 2012.
 
P.50 掲載の参考文献
1) 医薬品医療機器総合機構 : 医薬品医療機器情報提供ホームページ http://www.info.pmda.go.jp/index.html
 
P.55 掲載の参考文献
1) 日本老年医学会 : 高齢者に対する適切な医療提供の指針 http://www.jpn-geriat-soc.or.jp/proposal/pdf/geriatric_care_GL.pdf
 
2) American Geriatrics Society 2012 Beers Criteria Update Expert Panel : American Geriatrics Society updated Beers Criteria for potentially inappropriate medication use in older adults. J Am Geriatr Soc 60 : 616-631, 2012.
 
3) 日本老年医学会編 : 高齢者の安全な薬物療法ガイドライン 2005. メジカルビュー社, 2005.
 
4) Gallagher P, et al. : STOPP (Screening Tool of Older Person's Prescriptions) and START (Screening Tool to Alert doctors to Right Treatment). Consensus validation. Int J Clin Pharmacol Ther 462 : 72-83, 2008.
 
5) Pouyanne P, et al. : Admissions to hospital caused by adverse drug reactions ; cross sectional incidence study. French Pharmacovigilance Centres. BMJ 320 : 1036, 2000.
PubMed
6) Rothschild JM, et al. : Preventable medical injuries in older patients. Arch Intern Med 160 : 2717-2728, 2000.
PubMed
7) 鳥羽研二ほか : 老年者の薬物療法. 薬剤起因性疾患. 日老医会誌 36 : 181-185, 1999.
 
8) 秋下雅弘ほか : 高齢者薬物療法の問題点 ; 大学病院老年科における薬物有害作用の実態調査. 日老医会誌 41 : 303-306, 2004.
 
9) Kojima T, et al. : High risk of adverse drug reactions in elderly patients taking six or more drugs ; analysis of inpatient database. Geriatr Gerontol Int 12 : 761-762, 2012.
PubMed
10) Van der Linden PD, et al. : Fluoroquinolones and risk of Achilles tendon disorders ; case control study. BMJ 324 : 1306-1307, 2002.
PubMed
11) Granowitz EV, et al. : Antibiotic Adverse Reactions and Drug Interactions. Crit Care Clin 24 : 421-442, 2008.
PubMed
12) Reinbolt RE, et al. : Symptomatic Treatment of Infections in Patients with Advanced cancer Receving Hospice Care. J Pain Symptom Manage 30 : 175-182, 2005.
 
P.58 掲載の参考文献
1) 倉田なおみ, 藤島一郎監修 : 内服薬経管ハンドブック 第2版-簡易懸濁法可能医薬品一覧. じほう, 2006.
 
2) 石田志朗, 岡野善郎 : 配合変化を予測するための懸濁液pH情報を知りたい! 薬局 60 : 2929-2936, 2009.
Medical*Online
3) Xu XM, et al. : Effect of Ionic Strength on the Temperature-Dependent Behavior of Hydroxypropyl Methylcellulose Solution and Matrix Tablet. J Appl Polym Sci 102 : 4066-4074, 2006.
 
4) 倉田なおみ, 今野勉 : 添加物から製剤特性を認識し調剤に活かそう. 調剤と情報 18 : 1385-1388, 2012.
Medical*Online
5) 賀勢泰子 : 簡易懸濁法の留意点-配合変化を中心に. 薬事 48 : 723-730, 2006.
Medical*Online
6) Beringer P, et al. : Absolute bioavailability and pharmacokinetics of linezolid in hospitalized patients given enteral feedings. Antimicrob Agents Chemother 49 : 3676-3681, 2005.
PubMed
7) Burkhardt O, et al. : Effects of enteral feeding on the oral bioavailability of moxifloxacin in healthy volunteers. Clin Pharmacokinet 44 : 969-976, 2005.
PubMed
P.65 掲載の参考文献
1) Long SS, et al. : Enteroviruses and Parechoviruses. Principle and Practice of Pediatric Infectious Diseases, 4th ed. p. 1179, Elsevier, Philadelphia, 2012.
 
2) Pickerling LK, et al. (ed) : Respiratory Syncytial virus. Red Book 2012 Report of the Committee on Infectious Diseases, 29ed. p. 609, American Academy of Pediatrics, 2012.
 
3) Zaidi AK, et al. : Community-based treatment of serious bacterial infections in newborns and young infants ; a randomized controlled trial assessing three antibiotic regimens. Pediatr Infect Dis J 31 (7) : 667-672, 2012.
 
4) Volovitz B, et al. : Absence of tooth staining with doxycycline treatment in young children. Clin Pediatr (Phila) 46 (2) : 121-126, 2007.
PubMed
5) Adefurin A, et al. : Ciprofloxacin safety in paediatrics ; a systematic review. Arch Dis Child 96 (9) : 874-880, 2011.
PubMed
6) Kenealy T, Arroll B : Antibiotics for the common cold and acute purulent rhinitis. Cochrane Database Syst Rev 6 : CD000247, 2013.
PubMed
7) Sanchez AR, et al. : Tetracycline and other tetracycline-derivative staining of the teeth and oral cavity. Int J Dermatol 43 (10) : 709-715, 2004.
PubMed
P.68 掲載の参考文献
1) Roger KF, et al. : Drugs in pregnancy and lactation. Lippincott Williams & Wilkins, 2011.
 
2) 伊藤真也, 村島温子編 : 薬物治療コンサルテーション妊娠と授乳. 南山堂, 2010.
 
P.73 掲載の参考文献
1) Tamma PD, et al. : Combination therapy for treatment of infections with gram-negative bacteremia. Clin Microbiol Rev 25 (3) : 450-470, 2012.
 
2) Brito V, Niederman MS : Healthcare-associated pneumonia is a heterogeneous disease, and all patients do not need the same broad-spectrum antibiotic therapy as complex nosocomial pneumonia. Curr Opin Infect Dis 22 (3) : 316-325, 2009.
 
3) Martin-Loeches I, et al. : Potentially resistant microorganisms in intubated patients with hospital-acquired pneumonia ; the interaction of ecology, shock and risk factors. Intensive Care Med 39 (4) : 672-681, 2013.
PubMed
4) Shorr AF, et al. : Validation of a clinical score for assessing the risk of resistant pathogens in patients with pneumonia presenting to the emergency department. Clin Infect Dis 54 (2) : 193-198, 2012.
 
5) Zilberberg MD, et al. : Antimicrobial therapy escalation and hospital mortality among patients with health-care-associated pneumonia ; a single-center experience. Chest 134 (5) : 963-968, 2008.
PubMed
6) Rybak MJ, et al. : Nephrotoxicity of vancomycin, alone and with an aminoglycoside. J Antimicrob Chemother 25 (4) : 679-687, 1990.
PubMed
P.77 掲載の参考文献
1) Dellit TH, et al. : Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship. Clin Infect Dis 44 (2) : 159-177, 2007.
 
2) Takesue Y, et al. : Impact of hospital-wide programme of heterogeneous antibiotic use on the development of antibiotic-resistant Gram-negative bacteria. J Hosp Infect 75 (1) : 28-32, 2010.
PubMed
P.82 掲載の参考文献
1) Osenbach RK, Loftus CM : Diagnosis and management of brain abscess. Neurosurg Clin N Am 3 (2) : 403-420, 1992.
PubMed
2) Bartlett JG : Experimental aspects of intraabdominal abscess. Am J Med 76 (5A) : 91-98, 1984.
PubMed
3) Hansson L, et al. : Standardized intraabdominal abscess formation with generalized sepsis ; pathophysiology in the rat. Eur Surg Res 17 (3) : 155-159, 1985.
PubMed
4) Hays RC, Mandell GL : PO2, pH, and redox potential of experimental abscesses. Proc Soc Exp Biol Med 147 (1) : 29-30, 1974.
PubMed
5) Bryant RE, et al. : beta-Lactamase activity in human pus. J Infect Dis 142 (4) : 594-601, 1980.
PubMed
6) Simmen HP, et al. : Analysis of pH, pO2 and pCO2 in drainage fluid allows for rapid detection of infectious complications during the follow-up period after abdominal surgery. Infection 22 (6) : 386-389, 1994.
PubMed
7) Wagner C, et al. : Principles of antibiotic penetration into abscess fluid. Pharmacology 78 (1) : 1-10, 2006.
PubMed
8) Bamberger DM : Outcome of medical treatment of bacterial abscesses without therapeutic drainage ; review of cases reported in the literature. Clin Infect Dis 23 (3) : 592-603, 1996.
PubMed
9) Lipsky BA, et al. : Diagnosis and treatment of diabetic foot infections. Plast Reconstr Surg 117 (7 Suppl) : 212S-238S, 2006.
PubMed
10) Osmon DR, et al. : Diagnosis and management of prosthetic joint infection ; clinical practice guidelines by the Infectious Diseases Society of America. Clin Infect Dis 56 (1) : e1-e25, 2013.
 
P.86 掲載の参考文献
1) Schmitz FJ, Fluit AC : Mechanisms of antibacterial resistance. Infectious diseases, 3rd ed (Cohen J, et al. eds). pp. 1308-1322, Mosby, 2010.
 
2) Pfaller MA : Antifungal drug resistance ; mechanisms, epidemiology, and consequences for treatment. Am J Med 125 (Suppl 1) : S3-13, 2012.
 
P.92 掲載の参考文献
1) Freifeld AG, et al. : Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer ; 2010 update by the Infectious Diseases Society of America. Clin Infect Dis 52 (4) : e56-93, 2011.
 
2) Masaoka T : Evidence-based recommendations for antimicrobial use in febrile neutropenia in Japan ; executive summary. Clin Infect Dis 39 (Suppl 1) : S49-52, 2004.
 
3) Klastersky J, et al. : The Multinational Association for Supportive Care in Cancer risk index ; A multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol 18 (16) : 3038-3051, 2000.
PubMed
4) Kern WV, et al. : Oral antibiotics for fever in low-risk neutropenic patients with cancer ; a double-blind, randomized, multicenter trial comparing single daily moxifloxacin with twice daily ciprofloxacin plus amoxicillin/clavulanic acid combination therapy--EORTC infectious diseases group trial XV. J Clin Oncol 31 (9) : 1149-1156, 2013.
 
5) Paul M, et al. : Beta lactam monotherapy versus beta lactam-aminoglycoside combination therapy for sepsis in immunocompetent patients ; systematic review and meta-analysis of randomised trials. BMJ 328 (7441) : 668, 2004.
PubMed
6) Cordonnier C, et al. : Empirical versus preemptive antifungal therapy for high-risk, febrile, neutropenic patients ; a randomized, controlled trial. Clin Infect Dis 48 (8) : 1042-1051. 2009.
PubMed
P.102 掲載の参考文献
1) American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference : definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 20 : 864-874, 1992.
PubMed
2) Vincent JL, et al. : International study of the prevalence and outcomes of infection in intensive care units. JAMA 302 : 2323-2329, 2009.
 
3) Dellinger RP, et al. : Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock. Crit Care Med 32 : 858-873, 2004.
PubMed
4) Dellinger RP, et al. : Surviving Sepsis Campaign ; International guidelines for management of severe sepsis and septic shock ; 2008. Crit Care Med 36 : 296-327, 2008.
PubMed
5) Dellinger RP, et al. : Surviving sepsis campaign ; international guidelines for management of severe sepsis and septic shock ; 2012. Crit Care Med 41 : 580-637, 2013.
PubMed
6) 日本集中治療医学会Sepsis Registry委員会 : 日本版敗血症診療ガイドライン. 日集中医誌 20 : 124-173, 2013.
 
7) Trotman RL, et al. : Antibiotic dosing in critically ill adult patients receiving continuous renal replacement therapy. Clin Infect Dis 41 : 1159-1166, 2005.
PubMed
P.111 掲載の参考文献
1) Ehrenkranz NJ, Pfaff SJ : Mediastinitis complicating cardiac operations ; evidence of postoperative causation. Rev Infect Dis 13 (5) : 803-814, 1991.
PubMed
2) Mangram AJ, et al. : Guideline for prevention of surgical site infection, 1999. Hospital Infection Control Practices Advisory Committee. Infect Control Hosp Epidemiol 20 (4) : 250-278, 1999.
PubMed
3) Hidron AI, et al. : NHSN annual update ; antimicrobial-resistant pathogens associated with healthcare-associated infections ; annual summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2006-2007. Infect Control Hosp Epidemiol 29 (11) : 996-1011, 2008.
 
4) Bratzler DW, et al. : Clinical practice guidelines for antimicrobial prophylaxis in surgery. Am J Health Syst Pharm 70 (3) : 195-283, 2013.
 
5) Bratzler DW, et al. : Antimicrobial prophylaxis for surgery ; an advisory statement from the National Surgical Infection Prevention Project. Clin Infect Dis 38 (12) : 1706-1715, 2004.
PubMed
6) Gould FK, et al. : Guidelines (2008) for the prophylaxis and treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections in the United Kingdom. J Antimicrob Chemother 63 (5) : 849-861, 2009.
PubMed
7) Falagas ME, Karageorgopoulos DE : Adjustment of dosing of antimicrobial agents for bodyweight in adults. Lancet 375 (9710) : 248-251, 2010.
PubMed
8) Edmiston CE, et al. : Perioperative antibiotic prophylaxis in the gastric bypass patient ; do we achieve therapeutic levels? Surgery 136 (4) : 738-747, 2004.
PubMed
9) Steinberg JP, et al. : Timing of antimicrobial prophylaxis and the risk of surgical site infections ; results from the Trial to Reduce Antimicrobial Prophylaxis Errors. Ann Surg 250 (1) : 10-16, 2009.
PubMed
10) Harbarth S, et al. : Prolonged antibiotic prophylaxis after cardiovascular surgery and its effect on surgical site infections and antimicrobial resistance. Circulation 101 (25) : 2916-2921, 2000.
PubMed
11) Nateghian A, et al. : Risk factors for surgical site infections following open-heart surgery in a Canadian pediatric population. Am J Infect Control 32 (7) : 397-401, 2004.
 
12) Wilson W, et al. : Prevention of infective endocarditis ; guidelines from the American Heart Association ; a guideline from the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee, Council on Cardiovascular Disease in the Young, and the Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, and the Quality of Care and Outcomes Research Interdisciplinary Working Group. Circulation 116 (15) : 1736-1754, 2007.
 
13) Farbod F, et al. : Infective endocarditis and antibiotic prophylaxis prior to dental/oral procedures ; latest revision to the guidelines by the American Heart Association published April 2007. Int J Oral Maxillofac Surg 38 (6) : 626-631, 2009.
 
P.117 掲載の参考文献
1) Golan D, et al. (eds) : Pharmacokinetics. Principles of Phaemacology ; The Pathophysiologic Basis of Drug Therapy, 2nd ed. pp. 31-48, Wolters Kluwer, 2008.
 
2) Steingrimsdottir H, et al. : Bioavailability of aciclovir after oral administration of aciclovir and its prodrug valaciclovir to patients with leukopenia after chemotherapy. Antimicrob Agents Chemother 44 (1) : 207-209, 2000.
PubMed
3) Sloss A, Kubler P : Prescribing in liver disease. Aust Prescr 32 (2) : 32-35, 2009.
 
4) Verbeeck RK : Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction. Eur J Clin Pharmacol 64 (12) : 1147-1161, 2008.
PubMed
5) 日本腎臓学会編 : 腎機能の評価法 ; 成人. CKD診療ガイド 2012. pp. 18-21, 東京医学社, 2012.
 
6) Choi G, et al. : Principles of antibacterial dosing in continuous renal replacement therapy. Crit Care Med 37 (7) : 2268-2282, 2009.
PubMed
P.120 掲載の参考文献
1) Vert M, et al. : Terminology for biorelated polymers and applications (IUPAC Recommendations 2012). Pure Appl Chem 84 (2) : 377-410, 2012.
 
2) Romling U, Balsalobre C : Biofilm infections, their resilience to therapy and innovative treatment strategies. J Intern Med 272 (6) : 541-561, 2012.
PubMed
3) 豊福雅典ほか : バイオフィルム研究をめぐる最近の潮流. 感染症 43 (3) : 81-86, 98-100, 2013.
 
4) Hoiby N, et al. : Antibiotic resistance of bacterial biofilms. Int J Antimicrob Agents 35 (4) : 322-332, 2010.
PubMed
P.123 掲載の参考文献
1) 加治優一 : 抗真菌薬. 今日の眼疾患治療指針 第2版. pp. 844-847, 医学書院, 2007.
 
2) 鄭暁東 : 細菌性眼内炎. 眼の感染症. pp. 56-67, 金芳堂, 2010.
 
3) 西島良嗣 : 真菌性眼内炎. 眼の感染症. pp. 101-105, 金芳堂, 2010.
 
P.126 掲載の参考文献
1) Michalopoulos A, Papadakis E : Inhaled anti-infective agents ; Emphasis on colistin. Infection 38 : 81-88, 2010.
PubMed
2) Murray MP, et al. : A randomized controlled trial of nebulized gentamicin in non-cystic fibrosis bronchiectasis. Am J Respir Crit Care Med 183 : 491-499, 2011.
PubMed
3) Bitton D, et al. : Addition of inhaled tobramycin to ciprofloxacin for acute exacerbations of Pseudomonas aeruginosa infection in adult bronchiectasis. Chest 130 : 1503-1510, 2006.
 
4) Couch LA : Treatment with tobramycin solution for inhalation in bronchiectasis patients with Pseudomonas aeruginosa. Chest 120 : 114S-117S, 2001.
PubMed
5) Abu-Salah T, Dhand R : Inhaled antibiotic therapy for ventilator-associated tracheobronchitis and ventilator-associated pneumonia ; an update. Adv Ther 28 : 728-747, 2011.
PubMed
6) Tumbarello M, et al. : Effect of aerosolized colistin as adjunctive treatment on the outcomes of microbiologically documented ventilator-associated pneumonia caused by colistin-only susceptible gram-negative bacteria. Chest 144 : 1768-1775, 2013.
PubMed
7) Ghannam DE, et al. : Inhaled aminoglycosides in cancer patients with ventilator-associated Gram-negative bacterial pneumonia ; safety and feasibility in the era of escalating drug resistance. Eur J Clin Microbiol Infect Dis 28 : 253-259, 2009.
PubMed
8) Hamer DH : Treatment of nosocomial pneumonia and tracheobronchitis caused by multidrug-resistant Pseudomonas aeruginosa with aerosolized colistin. AJRCCM 162 : 328-330, 2000.
 
9) American Thoracic Society ; Infectious Disease Society of America : Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 171 : 388-416, 2005.
 
P.130 掲載の参考文献
1) 多田譲治 : 皮膚細菌感染症の治療. 最新皮膚科学大系 第14巻. pp. 33-52, 中山書店, 2003.
 
2) 西嶋攝子 : 抗菌外用薬. 最新皮膚科学大系 第2巻. pp. 35-39, 中山書店, 2003.
 
P.134 掲載の参考文献
1) Ridgeway S, et al. : Infection of the surgical site after arthroplasty of the hip. J Bone Joint Surg Br 87 (6) : 844-850, 2005.
PubMed
2) Anguita-Alonso P, et al. : Comparative study of antimicrobial release kinetics from polymethylmethacrylate. Clin Orthop Relat Res 445 : 239-244, 2006.
PubMed
3) Stevens CM, et al. : An articulated antibiotic spacer used for infected total knee arthroplasty ; a comparative in vitro elution study of Simplex and Palacos bone cements. J Orthop Res 23 (1) : 27-33, 2005.
PubMed
4) Persson C, et al. : Mechanical effects of the use of vancomycin and meropenem in acrylic bone cement. Acta Orthop 77 (4) : 617-621, 2006.
PubMed
5) Anagnostakos K, et al. : In vitro evaluation of antibiotic release from and bacteria growth inhibition by antibiotic-loaded acrylic bone cement spacers. J Biomed Mater Res B Appl Biomater 72 (2) : 373-378, 2005.
PubMed
6) Hsieh PH, et al. : Liquid gentamicin and vancomycin in bone cement ; a potentially more cost-effective regimen. J Arthroplasty 24 (1) : 125-130, 2009.
PubMed
7) Baleani M, et al. : Biological and biomechanical effects of vancomycin and meropenem in acrylic bone cement. J Arthroplasty 23 (8) : 1232-1238, 2008.
PubMed
8) van Huyssteen AL, Bracey DJ : Chlorhexidine and chondrolysis in the knee. J Bone Joint Surg Br 81 (6) : 995-996, 1999.
PubMed
9) Reading AD : Chlorhexidine and chondrolysis in the knee. J Bone Joint Surg Br 82 (4) : 620, 2000.
PubMed
10) Marberry KM, et al. : Surfactant wound irrigation for the treatment of staphylococcal clinical isolates. Clin Orthop Relat Res (403) : 73-79, 2002.
PubMed
P.137 掲載の参考文献
1) Kotzampassi K, Giamarellos-Bourboulis EJ : Probiotics for infectious diseases ; more drugs, less dietary supplementation. Int J Antimicrob Agents 40 (4) : 288-296, 2012.
PubMed
2) Guarner F, Schaafsma GJ : Probiotics. Int J Food Microbiol 39 (3) : 237-238, 1998.
PubMed
3) Videlock EJ, Cremonini F : Meta-analysis ; probiotics in antibiotic-associated diarrhoea. Aliment Pharmacol Ther 35 (12) : 1355-1369, 2012.
PubMed
4) Hempel S, et al. : Probiotics for the prevention and treatment of antibiotic-associated diarrhea ; a systematic review and meta-analysis. JAMA 307 (18) : 1959-1969, 2012.
PubMed
5) Johnston BC, et al. : Probiotics for the prevention of Clostridium difficile-associated diarrhea ; a systematic review and meta-analysis. Ann Intern Med 157 (12) : 818-888, 2012.
 
6) Goldenberg JZ, et al. : Probiotics for the prevention of Clostridium difficile-associated diarrhea in adults and children. Cochrane Database Syst Rev 2013 May 31 ; 5 : CD006095.
PubMed
7) Cohen SH, et al. : Clinical practice guidelines for Clostridium difficile infection in adults ; 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA). Infect Control Hosp Epidemiol 31 (5) : 431-455, 2010.
 
8) Debast SB, et al. : European Society of Clinical Microbiology and Infectious Diseases (ESCMID) ; update of the treatment guidance document for Clostridium difficile infection (CDI). Clin Microbiol Infect 20 (Suppl 2) : 1-26, 2013.
 

II. 各論 : 色々な抗菌薬・抗微生物薬のQ & A～効くメカニズム・適応・留意点・薬剤耐性～

P.145 掲載の参考文献
1) Lodise TP Jr, et al. ; Piperacillin-tazobactam for Pseudomonas aeruginosa infection ; clinical implications of an extended-infusion dosing strategy. Clin Infect Dis 44 (3) : 357-363, 2007.
PubMed
2) Gilbert DN, et al. ; 戸塚恭一, 根本正良監修 : 日本語版サンフォード感染症治療ガイド 2013, 第43版. ライフサイエンス出版, 2013.
 
3) 青木眞 : レジデントのための感染症診療マニュアル 第2版. pp. 103-119, 医学書院, 2008.
 
P.148 掲載の参考文献
1) Park MA : Diagnosis and management of penicillin allergy. Mayo Clin Proc 80 : 405-410, 2005.
PubMed
2) 医薬品医療機器情報提供ホームページ http://www.info.pmda.go.jp/index.html
 
3) Salkind AR, et al. : The rational clinical examination. Is this patient allergic to penicillin? An evidence-baced analysis of the likelihood of penicillin allergy. JAMA 285 : 2498-2505, 2001.
 
4) Mackowiak PA : Drug fever ; mechanisms, maxims and misconceptions. Am J Med Sci 294 : 275-286, 1987.
PubMed
5) Solensky R : Penicillin-allergic patients ; Use of cephalosporins, carbapenem, and monobactam. Up To Date : 2013.
 
6) Yates AB : Management of patient with a history of allergy to beta-lactam antibiotics. Am J Med 121 : 572-576, 2008.
PubMed
7) Gueant JL, et al. : IgE-mediated hypersensitivity to cephalosporins. Curr Pharm Des 12 : 3335-3345, 2006.
PubMed
8) Romano A : Cephalosporin-allergic patients : Subsequent use of cephalosporin and related antibiotics. Up To Date : 2013.
 
9) Gruchalla RS, Pirmohamed M : Clinical practice. Antibiotic allergy. N Engl J Med 354 : 601-609, 2006.
PubMed
10) Abbo LM. et al. : Management of antimicrobial allergy by infectious disease physicians. JAMA Intern Med 173 : 1376-1377, 2013.
PubMed
11) Castells MC : Rapid drug desentization for immediate hypersensitivity reactions. Up To Date : 2013.
 
12) 岡田正人 : レジデントのためのアレルギー疾患診療マニュアル. pp. 189-272, 医学書院, 2006.
 
P.158 掲載の参考文献
1) Mandell GL, et al. (eds) : Cephalosporins. Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases, 7th ed. pp. 323-339, Churchill Livingstone, 2009.
 
2) Kucer's The Use of Antibiotics, 6th ed. A clinical review of antibacterial, antifungal, antiparasitic and antiviral drugs. pp. 257-438, CRC Press, 2010.
 
3) Gilbert DN, et al. ; 戸塚恭一, 根本正良監修 : 日本語版サンフォード感染症治療ガイド 2013, 第43版. ライフサイエンス出版, 2013.
 
4) 青木眞 : セフェム系抗生物質, レジデントのための感染症診療マニュアル 第2版. 医学書院, pp. 119-136, 2000.
 
P.161 掲載の参考文献
1) Baba H : Aztreonam. Kucers' The Use of Antibiotics, 6th ed. pp. 458-465, CRC Press, 2010.
 
2) Gilbert DN, et al. : The Sanford Guide To Antimicrobial Therapy 2013, 43rd ed. p. 95, Antimicrobial Therapy, Inc., 2013.
 
3) Antunez C, et al. : Immediate hypersensitivity reactions to penicillins and other betalactams. Curr Pharm Des 12 (26) 3327-3333, 2006.
PubMed
4) Perez Pimiento A, et al. : Aztreonam and ceftazidime ; evidence of in vivo cross allergenicity. Allergy 53 (6) : 624-625, 1998.
PubMed
5) To Investigate the Safety and Tolerability of Aztreonam-Avibactam http://www.clinicaltrials.gov/show/NCT01689207 (最終アクセス日 2013. 9. 30)
 
P.166 掲載の参考文献
1) Falagas ME, et al. : Clinical outcomes with extended or continuous versus short-term intravenous infusion of carbapenems and piperacillin/tazobactam ; a systematic review and meta-analysis Clin Infect Dis 56 (2) : 272-282, 2013.
 
2) Mandell DN, et al. (eds) : Carbapenems, Mandell, Douglas, and Bennett's Principles and practice of Infectious diseases, 7th ed. pp. 341-343, Churchill Livingstone, 2009.
 
3) Gilbert DN, et al. ; 戸塚恭一, 根本正良監修 : 日本語版サンフォード感染症治療ガイド 2013, 第43版. ライフサイエンス出版, 2013.
 
4) 乾賢一, 土井俊夫 : 腎機能別薬剤処方マニュアル, じほう, 2010.
 
P.171 掲載の参考文献
1) Mandell GL, et al. (eds) : Aminoglycosides. Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases, 7th ed. pp. 359-384, Churchill Livingstone, 2009.
 
2) Bliziotis IA, et al. : Impact of definitive therapy with beta-lactam monotherapy or combination with an aminoglycoside or a quinolone for Pseudomonas aeruginosa bacteremia. PLoS ONE 6 (10) : e26470. doi : 10. 1371/journal.pone.0026470.
 
3) Gilbert DN, et al. ; 戸塚恭一, 根本正良監修 : 日本語版サンフォード感染症治療ガイド 2012, 第43版. ライフサイエンス出版, 2013.
 
4) Avent ML, et al. : Current use of aminoglycosides : indications, pharmacokinetics and monitoring for toxicity. Intern Med J 41 : 441-449, 2011.
PubMed
P.177 掲載の参考文献
1) 日本呼吸器学会医療・介護関連肺炎 (NHCAP) 診療ガイドライン作成委員会編 : 治療区分の考え方. 医療・介護関連肺炎 (NHCAP) 診療ガイドライン. pp. 8-11, 日本呼吸器学会, 2011.
 
2) 日本呼吸器学会医療・介護関連肺炎 (NHCAP) 診療ガイドライン作成委員会編 : 抗菌薬の選択. 医療・介護関連肺炎 (NHCAP) 診療ガイドライン. pp. 21-26, 日本呼吸器学会, 2011.
 
3) Jacobs MR : Optimisation of antimicrobial therapy using pharmacokinetic and pharmacodynamic parameters. Clin Microbiol Infect 7 : 589-596, 2001.
PubMed
4) Ambrose PG, et al. : Pharmacodynamics of Fluoroquinolones against Streptococcus pneumoniae in Patients with community-acquired respiratory tract infections. Antimicrob Agents Chemother 45 (10) : 2793-2797, 2001.
PubMed
5) Otani T, et al. : In vitro and in vivo antibacterial activities of DK-507k, a novel fluoroquinolone. Antimicrob Agents Chemother 47 (12) : 3750-3759, 2003.
PubMed
6) 河野茂ほか : 肺炎球菌性市中肺炎に対するtosufloxacin tosilate治療効果. 日化療会誌 53 (1) : 11-19, 2005.
 
7) 河野茂ほか : 注射薬pazufloxacin 1回 1,000mg 1日2回投与時の細菌性肺炎を対象とした臨床第III相試験. 日化療会誌 58 (6) : 664-680, 2010.
 
8) GOLD (Global Initiative for Chronic Obstructive Lung Disease) : CHAPTER 5 : MANAGEMENT OF EXACERBATIONS, Pharmacologic Treatment, Antibiotics : 42 http://www.goldcopd.org/uploads/users/files/GOLD_Report_2013_Feb20.pdf
 
9) JAID/JSC感染症治療ガイド・ガイドライン作成委員会 : 気道感染症, 慢性呼吸器病変の急性細菌性増悪. JAID/JSC感染症治療ガイド 2011. pp. 107-110, 日本感染症学会・日本化学療法学会, 2012.
 
10) 日本結核病学会治療委員会 : 「結核医療の基準」の見直し-2008年. 日本結核病学会 http://www.kekkaku.gr.jp/hp/commit/commit3/V83N7P529-535-tiryou.pdf
 
P.181 掲載の参考文献
1) Li J, et al. : Antibiograms of multidrug-resistant clinical Acinetobacter baumannii ; promising therapeutic options for treatment of infection with colistin-resistant strains. Clin Infect Dis 45 : 594-598, 2007.
PubMed
2) Garonzik SM, et al. : Population pharmacokinetics of colistin methanesulfonate and formed colistin in critically ill patients from a multicenter study provide dosing suggestions for various categories of patients. Antimicrob Agents Chemother 55 : 3284-3294, 2011.
PubMed
3) Li J, et al. : Colistin ; the re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infections. Lancet Infect Dis 6 : 589-601, 2006.
PubMed
4) Petrosillo N, et al. : Treatment of carbapenem-resistant Klebsiella pneumoniae ; the state of the art. Expert Rev Anti Infect Ther 11 : 159-177, 2013.
PubMed
5) Zavascki AP, et al. : Combination therapy for carbapenem-resistant Gram-negative bacteria. Expert Rev Anti Infect Ther 11 (12) : 1333-1353, 2013.
PubMed
P.186 掲載の参考文献
1) Daum RS : Clinical practice. Skin and soft-tissue infections caused by methicillin-resistant Staphylococcus aureus. N Engl J Med 357 : 380-390, 2007.
PubMed
P.190 掲載の参考文献
1) Muratani T, et al. : Single dose 1g ceftriaxone for urogenital and pharyngeal infection caused by Neisseria gonorrhoeae. Int J Urol 15 : 837-842, 2008.
 
2) Ohnishi M, et al. : Ceftriaxone-resistant Neisseria gonorrhoeae, Japan. Emerg Infect Dis 17 : 148-149, 2011.
PubMed
P.194 掲載の参考文献
1) Stevens DL, et al. : The Eagle effect revisited ; efficacy of clindamycin, erythromycin, and penicillin in the treatment of streptococcal myositis. J Infect Dis 158 : 23-28, 1988.
PubMed
2) Gemmell CG, et al. : Potentiation of opsonization and phagocytosis of Streptococcus pyogenes following growth in the presence of clindamycin. J Clin Invest 67 : 1249-1256, 1981.
PubMed
3) Yoshizawa S, et al. : Virulence-suppressing effects of linezolid on methicillin-resistant Staphylococcus aureus ; possible contribution to early defervescence. Antimicro Agents Chemother 56 (4) : 1744, 2012.
 
4) Desaki M, et al. : Molecular mechanisms of anti-inflammatory action of erythromycin in human bronchial epithelial cells ; possible role in the signaling pathway that regulates nuclear factor-B activation. Antimicrob Agents Chemother 48 : 1581-1585, 2004.
 
5) Tateda K, et al. : Potential of macrolide antibiotics to inhibit protein synthesis of Pseudomonas aeruginosa ; suppression of virulence factors and stress response. J Infect Chemother 6 : 1-7, 2000.
PubMed
6) Shinkai M, et al. : Macrolide antibiotics as immunomodulatory medications ; proposed mechanisms of action. Pharmacol Ther 117 : 393-405, 2008.
PubMed
7) Gemmell CG, Ford CW : Virulence factor expression by Gram-positive cocci exposed to subinhibitory concentrations of linezolid. J Antimicrob Chemother 50 : 665-672, 2002.
PubMed
8) Coyle EA, et al. : Influences of linezolid, penicillin, and clindamycin, alone and in combination, on streptococcal pyrogenic exotoxin a release. Antimicrob Agents Chemother 47 (5) : 1752-1755, 2003.
PubMed
9) Garcia-Roca P, et al. : Lenezolid diminishes inflammatory cytokine production from human peripheral blood mononuclear cells. Arch Med Res 37 (1) : 31-35, 2006.
PubMed
P.201 掲載の参考文献
1) Nguyen M, et al. : Carbapenem-resistant Klebsiella pneumonia bacteremia ; factors correlated with clinical and microbiological outcomes. Diagn Microbiol Infact Dis 67 (2) : 180-184, 2010.
 
2) Tasina E, et al. : Efficacy and safety of tigecycline for the treatment of infectious diseases ; a meta-analysis. Lancet Infect Dis 11 : 834-844, 2011.
PubMed
3) Yahav D, et al. : Efficacy and safety of tigecycline ; a systematic review and meta-analysis. J Antimicrob Chemother 66 : 1963-1971, 2011.
PubMed
4) Petrosillo N, et al. : Treatment of carbapenem-resistant Klebsiella pneumoniae ; the state of the art. Expert Rev Anti Infect Ther 11 : 159-177, 2013.
PubMed
5) Zavascki AP, et al. : Combination therapy for Carbapenem-resistant Gram-negative bacteria. Expert Rev Anti Infect Ther 11 (12) : 1333-1353, 2013.
PubMed
6) 日本化学療法学会チゲサイクリン適正使用のための手引き作成委員会編 : チゲサイクリン適正使用のための手引き 2014. 日本化学療法学会雑誌 62 (3) : 311-366, 2014.
 
P.204 掲載の参考文献
1) Hendlin D, et al. : Phosphonomycin, a new antibiotic produced by strains of streptomyces. Science 166 : 122-123, 1969.
PubMed
2) Grayson ML, et al. : Fosfomycin. Kucers' The Use of Antibiotics, 6th ed. A clinical review of antibacterial, antifungal and antiviral drugs. pp. 935-942, ASM Press, 2010.
 
3) 鶴岡勉 : Fosfomycinの抗菌作用機構の解明に関する最近の知見. 日化療会誌 47 (3) : 115-128, 1999.
 
4) Bergan T : Pharmacokinetic comparison between fosfomycin and other phosphonic acid derivatives. Chemotherapy 36 (Suppl 1) : 10-18, 1990.
PubMed
5) Matsumoto T, et al. : Clinical effects of 2 days of treatment by fosfomycin calcium for acute uncomplicated cystitis in women. J Infect Chemother 17 (1) : 80-86, 2011.
PubMed
6) Ikeda K, et al. : Effect of early fosfomycin treatment on prevention of hemolytic uremic syndrome accompanying Escherichia coli O157 : H7 infection. Clin Nephrol 52 (6) : 357-362, 1999.
PubMed
P.209 掲載の参考文献
1) Mandell GL, et al. (eds) : Glycopeptides. Mandell, Douglas, and Bennett's Principles and practice of Infectious diseases, 7th ed. pp. 449-459, Churchill Livingstone, 2009.
 
2) Svetitsky S, et al. : Comparative efficacy and safety of vancomycin versus teicoplanin ; systematic review and meta-analysis. Antimicrob Agents Chemother 55 : 4069-4079, 2009.
 
3) Cavalcanti AB, et al. : Teicoplanin versus vancomycin for proven or suspected infection (Review) Cochrane Database of Systematic Reviews 2010, Issue 6. The Cochrane Collaboration.
 
4) Rybak MJ, et al. : Vancomycin Therapeutic Guidelines ; a summary of consensus recommendations from the infectious diseases Society of America, the American Society of Health-System Pharmacists, and the Society of Infectious Diseases Pharmacists. Clin Infect Dis 49 (3) : 325-327, 2009.
 
5) Gilbert DN, et al. ; 戸塚恭一, 根本正良監修 : 日本語版サンフォード感染症治療ガイド 2013, 第43版. ライフサイエンス出版, 2013.
 
P.211 掲載の参考文献
1) Mandell GL, et al. (eds) : Streptogramins. Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases, 7th ed. pp. 459-462, Churchill Livingstone, 2009.
 
2) Grayson ML, et al. : Quinupristin-Dalfopristin. Kucers' The Use of Antibiotics, 6th ed. A Clinical Review of Antibacterial, Antifungal and Antiviral Drugs. pp. 920-929, ASM Press, 2010.
 
P.216 掲載の参考文献
1) Jiang H, et al. : Linezolid versus vancomycin or teicoplanin for nosocomial pneumonia ; meta-analysis of randomised controlled trials. Eur J Clin Microbiol Infect Dis 32 : 1121-1128, 2013.
PubMed
2) Wunderink RG, et al. : Linezolid in methicillin-resistant Staphylococcus aureus nosocomial pneumonia ; a randomized, controlled study. Clin Infect Dis 54 (5) : 621-629, 2012.
PubMed
3) Falagas ME, et al. : Linezolid for the treatment of patients with endocarditis ; a systematic review of the published evidence. J Antimicrob Chemother 58 : 273-280, 2006.
PubMed
4) Liu C, et al. : Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis 52 (3) : e18-55, 2011.
 
5) Humphries RM, et al. : A current perspective on daptomycin for the clinical microbiologist. Clin Microbiol Rev 26 (4) : 759-780, 2013.
PubMed
P.221 掲載の参考文献
1) Hauser AR : Antibiotic Basics for Clinicians 2007. p. 81, Wolters Kluwer, Lippincott Williams & Wilkins, 2007.
 
2) Sulfamethoxazole and trimethoprim injection. FDA approved product information http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=b89b5502-ce87-45a6-a43c-9891da3cfca4.
 
3) Cunha BA (ed) : Antibiotic Essentials 2013, 12th ed. pp. 515-516, 707-708, Jones & Bartlett Learning, 2013.
 
4) Kainer G, Rosenberg AR : Effect of co-trimoxazole on the glomerular filtration rate of healthy adults. Chemotherapy 27 (4) : 229-232, 1981.
PubMed
5) Masters PA, et al. : Trimethoprim-sulfamethoxazole revisited. Arch Intern Med 163 (4) : 402-410, 2003.
PubMed
6) Zinner S : Sulfonamides and Trimethoprim. Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases, 7th ed. p. 476, Churchill Livingstone, 2010.
 
P.226 掲載の参考文献
1) Houghton GW, et al. : The pharmacokinetics of oral and intravenous metronidazole in man. J Antimicrob Chemother 5 : 621-623, 1979.
 
2) Hecht DW, et al. : CLSI M11-A8 Methods for Antimicrobial Susceptibility Testing of Anaerobic Bacteria ; Approved Standard, 8th ed. pp. 33-34, Clinical and Laboratory Standards Institute, 2012.
 
3) Cohen SH, et al. : Clinical practice guidelines for Clostridium difficile infection in adults ; 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA). Infect Control Hosp Epidemiol 31 (5) : 431-455, 2010.
 
4) 和田真太郎ほか : Helicobacter pyloriの薬剤感受性試験法の検討と耐性株の出現状況. 感染症誌 77 (4) : 187-194, 2003.
 
P.234 掲載の参考文献
1) 日本結核病学会治療委員会 : 「結核医療の基準」の見直し-2008年. 結核 83 : 529-535, 2008.
 
2) 日本結核病学会編 : 結核診療ガイドライン 第2版. 南江堂, 2012.
 
3) Blumberg HM, et al. ; American Thoracic Society, Centers for Disease Control and Prevention and the Infectious Disease Society : American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America ; treatment of tuberculosis. Am J Respir Crit Care Med 167 : 603-662, 2003.
 
4) 日本結核病学会治療委員会 : 結核治療におけるレボフロキサシンの使用方法について. 「結核医療の基準」の見直し-2008年への追補. 結核 85 : 7, 2010.
 
5) 花田和 : PK/PD理論に基づく抗酸菌症の治療. 結核 85 : 853-859, 2010.
 
6) 日本結核病学会治療委員会 : リファマイシン系抗生物質リファブチンの結核への使用について (「結核医療の基準」の見直し-2008年への追補). 結核 83 : 679, 2008.
 
7) World Health Organization : Guidelines for treatment of tuberculosis, 4th ed. WHO, Geneva, 2010.
 
8) 日本結核病学会治療委員会 : 抗結核薬使用中の肝障害への対応について. 結核 82 : 115-118, 2007.
 
P.241 掲載の参考文献
1) 深在性真菌症のガイドライン作成委員会編 : 深在性真菌症の診断・治療ガイドライン 2014. 協和企画, 2014.
 
2) 日本化学療法学会抗菌薬TDMガイドライン作成委員会, 日本TDM学会TDMガイドライン策定委員会-抗菌薬領域編 : 抗菌薬TDMガイドライン. 2012.
 
3) Park WB, et al. : The effect of therapeutic drug monitoring on safety and efficacy of voriconazole in invasive fungal infections ; a randomized controlled trial. Clin Infect Dis 55 : 1080-1087, 2012.
PubMed
4) Pappas PG, et al. : Alopecia associated with fluconazole therapy. Ann Intern Med 123 : 354-357, 1995.
PubMed
5) Ahmad SR, et al. : Congestive heart failure associated with itraconazole. Lancet 357 : 1766-1767, 2001.
PubMed
6) Cowen EW, et al. : Chronic phototoxicity and aggressive squamous cell carcinoma of the skin in children and adults during treatment with voriconazole. J Am Acad Dermatol 62 : 31-37, 2010.
PubMed
7) Andes D, et al. : In vivo pharmacokinetics and pharmacodynamics of a new triazole, voriconazole, in a murine candidiasis model. Antimicrob Agents Chemother 47 : 3165-3169, 2003.
 
8) Al-saigh R, et al. : In vitro pharmacokinetic/pharmacodynamic modeling of voriconazole activity against Aspergillus Species in a new In vitro dynamic model. Antimicrob Agents Chemother 56 : 5321-5327, 2012.
 
9) Pappas PG, et al. : Clinical practice guidelines for the management of candidiasis : 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 48 : 503-535, 2009.
 
10) Walsh TJ, et al. : Treatment of aspergillosis ; clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 46 (3) : 327-360, 2008.
 
11) Cowen LE : The evolution of fungal drug resistance : modulating the trajectory from genotype to phenotype. Nat Rev Microbiol 6 : 187-198, 2008.
PubMed
12) 泉川公一ほか : 薬剤耐性アスペルギルスの現状, 耐性獲得機序と今後. 日本化学療法学会誌 61 : 149-156, 2013.
 
P.246 掲載の参考文献
1) 深在性真菌症のガイドライン作成委員会編 : 深在性真菌症の診断・治療ガイドライン 2014. 協和企画, 2014.
 
2) Pappas PG, et al. : Clinical practice guidelines for the management of candidiasis ; 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 48 : 503-535, 2009.
 
3) Walsh TJ, et al. : Treatment of aspergillosis ; clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 46 (3) : 327-360, 2008.
 
4) Pfaller MA, et al. : Frequency of decreased susceptibility and resistance to echinocandins among fluconazole-resistant bloodstream isolates of Candida glabrata. J Clin Microbiol 50 : 1199-1203, 2012.
PubMed
5) Alexander BD, et al. : Increasing echinocandin resistance in Candida glabrata ; clinical failure correlates with presence of FKS mutations and elevated minimum inhibitory concentrations. Clin Infect Dis 56 : 1724-1732, 2013.
PubMed
6) Arendrup MC : Update on antifungal resistance in Aspergillus and Candida. Clin Microbiol Infect 20 (Suppl 6) : 42-48, 2014.
 
P.252 掲載の参考文献
1) Hamill RJ : Amphotericin B formulation ; a comparative review of Efficacy and Toxicity. Drugs 73 : 919-934, 2013.
PubMed
2) Ostrosky-Zeichner L, et al. : Amphotericin B ; time for a new "gold standard". Clin Infect Dis 37 : 415-425, 2003.
PubMed
3) Freifeld AG, et al. : Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer ; 2010 update by the infectious diseases society of America. Clin Infect Dis 52 (4) : e56-93, 2011.
 
4) Pappas GP, et al. : Clinical practice guidelines for the management of candidiasis ; 2009 update by the infectious diseases society of America. Clin Infect Dis 48 : 503-535, 2009.
 
5) Walsh TJ, et al. : Treatment of aspergillosis ; clinical practice guidelines of infectious diseases society of America. Clin Infect Dis 46 : 327-360, 2008.
 
6) Perfect JR, et al. : Clinical practice guidelines for the management of cryptococcal disease ; 2010 update by the infectious diseases society of America. Clin Infect Dis 50 : 291-322, 2010.
 
7) Perea F, et al. : Antifungal resistance in pathogenic fungi. Clin Infect Dis 35 : 1073-1080, 2002.
 
P.254 掲載の参考文献
1) Hope WW, et al. : Derivation of an in vitro drug exposure breakpoint for flucytosine against Candida albicans and impact of the MIC, growth rate, and resistance genotype on the antifungal effect. Antimicrob Agents Chemother 50 : 3680-3688, 2006.
 
2) Perfect JR, et al. : Clinical practice guidelines for the management of cryptococcal disease ; 2010 update by the Infectious Diseases Society of America. Clin Infect Dis 50 : 291-322, 2010.
 
P.264 掲載の参考文献
1) McNicholl IR, Jacobson MA : Ganciclovir and Valganciclovir. Kucers' The Use of Antibiotics, 6th ed. pp. 2378-2402, ASM Press, 2010.
 
2) Mills J, Crowe SM : Foscarnet. Kucers' The Use of Antibiotics, 6th ed. pp. 2433-2455, ASM Press, 2010.
 
3) Andrei G, Snoeck R : Cidofovir. Kucers' The Use of Antibiotics, 6th ed. pp. 2403-2428, ASM Press, 2010.
 
4) Kotton CN, et al. : Updated international consensus guidelines on the management of cytomegalovirus in solid-organ transplantation. Transplantation 96 (4) : 333-360, 2013.
PubMed
5) 日本造血細胞移植学会 : 造血細胞移植ガイドライン-サイトメガロウイルス感染症 第2版 http://www.jshct.com/guideline/pdf/guideline_CMV_2.pdf (最終アクセス日 2013. 12. 10)
 
6) Lurain NS, Chou S : Antiviral drug resistance of human cytomegalovirus. Clin Microbiol Rev 23 (4) : 689-712, 2010.
PubMed
P.269 掲載の参考文献
1) 日本臨床内科医会インフルエンザ研究班編 : インフルエンザ診療マニュアル 2013-2014. pp. 22-30, 2013.
 
2) 日本小児感染症診療ガイドライン作成委員会 : 小児呼吸器感染症ガイドライン 2011. pp. 71-74. 協和企画, 2011.
 
3) 日本感染症学会提言～抗インフルエンザ薬の使用適応について (改訂版) http://www.kansensho.or.jp/influenza/pdf/110301soiv_teigen.pdf
 
4) 日本感染症学会 : 日本感染症学会提言 2012「インフルエンザ病院内感染対策の考え方について (高齢者施設を含めて) 」. http://www.kansensho.or.jp/influenza/pdf/1208_teigen.pdf
 
P.273 掲載の参考文献
1) Ghany M, Liang TJ : Drug targets and molecular mechanisms of drug resistance in chronic hepatitis B. Gastroenterology 132 : 1574-1585, 2007.
PubMed
2) Iloeje UH, et al. : Predicting cirrhosis risk based on the circulating hepatitis B viral load. Gastroenterology 130 : 678-686, 2006.
PubMed
3) Matsumoto A, et al. : Efficacy of lamivudine for preventing hepatocellular carcinoma in chronic hepatitis B ; a multicenter retrospective study of 2795 patients. Hepatol Res 32 : 173-184, 2005.
PubMed
4) Asselah T, Marcellin P : Interferon free therapy with direct acting antivirals for HCV. Liver Int 33 (Suppl 1) : 93-104, 2013.
PubMed
5) Lange CM, Zeuzem S : Perspectives and challenges of interferon-free therapy for chronic hepatitis C. J Hepatol 58 : 583-592, 2013.
PubMed
P.282 掲載の参考文献
1) 国内で流行するHIV遺伝子型および薬剤耐性株の動向把握と治療方法の確立に関する研究班.
 
P.290 掲載の参考文献
1) ヒューマンサイエンス振興財団政策創薬総合研究事業「輸入熱帯病・寄生虫に対する稀少疾病治療薬を用いた最適な治療法による医療対応の確立に関する研究」班編 : 寄生虫症薬物治療の手引き 2010, 第7.0版. pp. 1-28, 2010.
 
2) Abdi YA, et al. : Metronidazole, Handbook for tropical parasitic infections, 2nd ed. pp. 100-105, Taylor & Francis, London, 1995.
 
P.293 掲載の参考文献
1) Gilbert DN, et al. ; 戸塚恭一, 根本正良監修 : 日本語版サンフォード感染症治療ガイド 2013, 第43版. ライフサイエンス社, 2013.
 
2) Baddour LM, et al. : Infective endocarditis ; diagnosis, antimicrobial therapy, and management of complications ; a statement for healthcare professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, and the Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia, American Heart Association ; endorsed by the Infectious Diseases Society of America. Circulation 111 : e394-434, 2005.
 
3) Tunkel AR, et al. : Practice guidelines for the management of bacterial meningitis. Clin Infect Dis 39 : 1267-1284, 2004.
PubMed
4) Solomkin JS, et al. : Diagnosis and management of complicated intra-abdominal infection in adults and children ; guidelines by the Surgical Infection Society and the Infectious Diseases Society of America. Clin Infect Dis 50 : 133-164, 2010.
 
5) 日本化学療法学会 : コリスチンの適正使用に関する指針. 日化療会誌 60 : 446-468, 2012.
 
6) Debast SB, et al. : European Society of Clinical Microbiology and Infectious Diseases ; update of the treatment guidance document for Clostridium difficile infection. Clin Microbiol Infect 20 (Suppl 2) : 1-26, 2014.
 

書評

最近チェックした商品履歴

Loading...